Blue Jet Healthcare Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/cfwsxijrxcrdwbw4wmfjj2u8.pdf

Key Takeaways


The Cardiovascular Intermediate Surge

VK Singh: "Our capacities are often co-engineered and build-to-suit to support our go-to-market that is largely innovator-oriented."

Contrast Media: A Tale of Two Halves

Shiven Arora: "Yes. There would be a very high conviction around that, very, very high, yes."

Capacity Build-Out: Unit 2 Live, Unit 3 Next

VK Singh: "This change, when implemented, shall deliver higher and more consistent quality, be safer and have a lower physical and carbon footprint."

R&D and the Peptide Bet


Margins, Mix, and the Guidance That Wasn't

Ganesh Karuppannan: "We don't want to give any guidance at this stage because we also have the new R&D coming in, and we need to actually like make an assessment how the operating costs are going to be for FY 26."

The Moat: No Generics, Sticky Customers

VK Singh: "Saccharin has been on the market for 150 years. So, this was invented 150 years back. I think it's the most stable product, both in chemistry and demand."

Guidance & Commitments

CommitmentSpecificsTimeline
Contrast media capacity optimizationOptimize capacity utilizations for contrast mediaH1 2026
Unit 3 go-liveUnit 3 at Mahad to go liveH2 FY26
New advanced intermediate launchNew advanced intermediate to go liveQ1 FY26
EBITDA margin signalSustained Q3-level activity should yield EBITDA in excess of 35%-37%Conditional on turnover levels holding
R&D investment₹40 crore investment in R&D infrastructure and capabilitiesFY26
Backward integrationManufacture the one missing imported raw material for contrast media at own siteShort to medium term

Key Metrics

MetricQ3 FY25
Revenue₹318.4 cr, +53% QoQ and +91% YoY
EBITDA₹124 cr, +79% QoQ and +127% YoY
PAT₹99 cr, +70% QoQ and +208% YoY, highest ever quarterly profit
EBITDA margin39% of sales; 9M FY25 at 34.5%
PAT margin28.3% for 9M FY25
9M FY25 revenue₹689.5 cr, +31% YoY
9M FY25 pharmaceutical intermediates turnover₹266.3 cr, +352% YoY
9M FY25 contrast media segment turnover₹302.8 cr, degrowth of ~17%
Saccharin category 9M FY25 turnover₹103.8 cr, +10% YoY
Gross margin55% for 9M FY25, down 2 ppt due to product mix change
Total cash, investments and bank balance₹331.3 cr, down ₹21 cr vs September
Working capital increase₹120 cr in 9M FY25, predominantly for pharma intermediate inventory
R&D investment planned₹40 cr capex in FY26, with operating expense expected at ₹10–12 cr vs current ₹5–6 cr
Capacity addition (Unit 2)120 KL Phase 1 operational; 37 KL Phase 2 live with validation batches shipped
Cardiovascular product US prescription growth~15% QoQ retail prescription equivalent